Piramal Pharma listing: 5% lower circuit, key levels

Where Piramal Pharma stock stands now

Piramal Pharma share price was ₹195.64 as on 12 Nov 2025. Over the past six months, the share price was down 5.84%, and over the last one year, it was down 27.46%. The 52-week low for Piramal Pharma was ₹181.73, while the 52-week high was ₹283.9. These numbers frame the stock’s performance after it became a separately listed company following the demerger from Piramal Enterprises.

Listing day: stock hits the lower circuit

On its listing as a separate entity after the demerger from Piramal Enterprises, Piramal Pharma shares were locked in a 5% lower circuit at ₹192 on the BSE. Another listing-day snapshot in the text shows the stock debuted at ₹201.80 on the BSE and ₹200 on the NSE. After listing, it fell 5% to hit a lower circuit of ₹191.75 on the BSE, while it touched an intraday low of ₹190 on the NSE. The trading action was described as a lacklustre response from investors on debut.

Regulatory clearances that enabled the listing

The listing followed approvals and filings described in the text. Piramal Pharma received approval from SEBI to list shares on domestic stock exchanges. The demerger was part of a simplification of Piramal Enterprises’ corporate structure after it received approval from the National Company Law Tribunal (NCLT). The company said it had received a letter from SEBI and expected its shares to be listed on BSE and NSE.

Why the stock was placed in the ‘T’ group

According to the information cited, the securities of Piramal Pharma were admitted to trading in the ‘T’ group of securities. Since the company emerged from a demerger, the scrip was to be in the trade-for-trade segment for 10 trading days, which was expected to keep trading volume muted. This detail matters because the trade-for-trade framework changes how trades are settled and can influence near-term liquidity.

Demerger terms: how shareholders got Piramal Pharma shares

The scheme terms in the text specify the share entitlement clearly. As part of the demerger, four equity shares of face value ₹10 each of Piramal Pharma were issued and allotted for every one share of face value ₹2 held in Piramal Enterprises. The same ratio is repeated across the material, along with the point that shareholders received these Piramal Pharma shares in addition to their existing holding in Piramal Enterprises.

What Piramal Pharma does: three key business lines

Piramal Pharma Limited (PPL) operates with manufacturing capabilities across 15 global facilities and sells through a distribution network in over 100 countries, as stated. The company’s business model is described as comprising Contract Development and Manufacturing (CDMO), complex hospital generics, and India consumer healthcare. The portfolio includes Piramal Pharma Solutions (PPS), Piramal Critical Care (PCC), and the India consumer healthcare business selling over-the-counter products.

Growth and investment plans highlighted by Motilal Oswal

Motilal Oswal noted that the CDMO business registered a 10% compounded annual growth rate (CAGR) over FY17-22, driven by focused efforts across emerging bio-pharma and big pharma. The report also pointed to high entry barriers and a shift to a more integrated network as growth drivers for the CDMO business. The brokerage expected continued investments of $157 million to expand capacity and attract customers through differentiated offerings. It also cited a healthy pipeline of developmental projects across clinical phases.

Revenue and valuation markers mentioned in the text

Motilal Oswal’s expectation in the text was that CDMO revenues would exhibit a 10% CAGR over FY22-24 to ₹480 crore, supported by a pipeline with visibility of revenues over the next four to five years. The brokerage also shared a sum-of-the-parts approach: it valued the CDMO business, CHG, and ICH based on 16x, 12x, and 18x FY24E EV/EBITDA, respectively, and valued the Allergan JV (49% stake) at 18x FY24E PE. It set a target price of ₹210, indicating limited upside from the then market price, as stated.

Trading activity and market-cap snapshots around listing

The text notes a surge in activity on listing day, with around 53 lakh shares changing hands across BSE and NSE, while market capitalisation stood at ₹22,881.9 crore by 12:20 pm. It also states that Piramal Enterprises traded 1% higher at ₹827.25 per share around 10:10 am during the same broader period of coverage. Separately, another snapshot included in the material says that “as we write this article” PEL market cap was ₹19,153 crore and Piramal Pharma’s was ₹11,020 crore, totaling ₹30,173 crore, described as a 37% erosion post demerger. That same note mentioned PEL trading at ₹802 per share and Piramal Pharma trading at ₹92 per share.

Key numbers at a glance

Why the demerger and listing mattered for investors

The text positions the demerger as a corporate structure simplification, creating two distinct listed entities: Piramal Enterprises focused on the NBFC business, and Piramal Pharma focused on pharmaceuticals. The listing also made the pharma business directly comparable with other listed pharma peers, rather than being embedded inside a diversified parent. At the same time, the listing-day fall and trade-for-trade classification highlighted near-term market caution. Brokerage commentary focused on CDMO-led growth, capacity expansion and a development pipeline, alongside valuation multiples and a target price.

Conclusion

Piramal Pharma’s debut after the Piramal Enterprises demerger came with a 5% lower circuit move and a trade-for-trade trading classification for the initial period, according to the text. Subsequent price data shows the stock at ₹195.64 as on 12 Nov 2025, with a 52-week range of ₹181.73 to ₹283.9. The market’s focus remains on the company’s CDMO trajectory, planned investments, and execution across its CDMO, hospital generics and consumer healthcare businesses, as outlined in the brokerage and company descriptions included.